A detailed history of Jpmorgan Chase & CO transactions in Allovir, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 6,762 shares of ALVR stock, worth $6,018. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,762
Previous 30,184 77.6%
Holding current value
$6,018
Previous $22,000 81.82%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$0.72 - $0.82 $16,863 - $19,206
-23,422 Reduced 77.6%
6,762 $4,000
Q1 2024

May 10, 2024

SELL
$0.64 - $0.78 $214,229 - $261,091
-334,733 Reduced 91.73%
30,184 $22,000
Q4 2023

Feb 12, 2024

SELL
$0.68 - $2.39 $471,288 - $1.66 Million
-693,071 Reduced 65.51%
364,917 $248,000
Q3 2023

Nov 14, 2023

SELL
$2.15 - $3.64 $78,980 - $133,715
-36,735 Reduced 3.36%
1,057,988 $2.27 Million
Q2 2023

Aug 11, 2023

BUY
$3.17 - $5.82 $345,894 - $635,049
109,115 Added 11.07%
1,094,723 $3.72 Million
Q1 2023

May 18, 2023

BUY
$3.94 - $7.05 $93,748 - $167,747
23,794 Added 2.47%
985,608 $3.88 Million
Q1 2023

May 11, 2023

SELL
$3.94 - $7.05 $929 - $1,663
-236 Reduced 0.02%
961,814 $3.79 Million
Q4 2022

Feb 13, 2023

BUY
$4.7 - $9.98 $1.66 Million - $3.52 Million
352,919 Added 57.94%
962,050 $4.94 Million
Q3 2022

Nov 14, 2022

SELL
$4.13 - $8.79 $688,371 - $1.47 Million
-166,676 Reduced 21.48%
609,131 $4.81 Million
Q2 2022

Aug 11, 2022

BUY
$3.26 - $7.06 $38,790 - $84,006
11,899 Added 1.56%
775,807 $3.03 Million
Q1 2022

May 11, 2022

BUY
$6.75 - $13.52 $1.12 Million - $2.24 Million
165,711 Added 27.7%
763,908 $5.16 Million
Q4 2021

Feb 10, 2022

SELL
$12.94 - $25.99 $1.93 Million - $3.88 Million
-149,302 Reduced 19.97%
598,197 $7.74 Million
Q3 2021

Nov 12, 2021

BUY
$16.97 - $25.06 $12.7 Million - $18.7 Million
747,499 New
747,499 $18.7 Million

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $82.8M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.